Showing results (191-200 of 286) with videos related to
Sort By:
Pageof 29
Cancer Immunology, Immunotherapy : CII|February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinomaSandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.Journal of the American Academy of Dermatology|June 10, 2021
Guidelines of care for the management of actinic keratosis: Executive summaryDaniel B Eisen, Maryam M Asgari, Daniel D Bennett, et al.Journal of the American Academy of Dermatology|April 6, 2021
Guidelines of care for the management of actinic keratosisDaniel B Eisen, Maryam M Asgari, Daniel D Bennett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.The Oncologist|September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patientsTristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.Pageof 29